Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to 7.44%.

  • Arcutis Biotherapeutics' EBITDA Margin rose 984000.0% to 7.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.13%, marking a year-over-year increase of 1263200.0%. This contributed to the annual value of 71.26% for FY2024, which is 3667000.0% up from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' EBITDA Margin is 7.44%, which was up 984000.0% from 19.36% recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' EBITDA Margin ranged from a high of 7.44% in Q3 2025 and a low of 14903.86% during Q3 2022
  • Over the past 4 years, Arcutis Biotherapeutics' median EBITDA Margin value was 148.86% (recorded in 2023), while the average stood at 1736.68%.
  • Per our database at Business Quant, Arcutis Biotherapeutics' EBITDA Margin soared by 147550100bps in 2023 and then soared by 334000bps in 2025.
  • Over the past 4 years, Arcutis Biotherapeutics' EBITDA Margin (Quarter) stood at 2415.03% in 2022, then skyrocketed by 80bps to 488.66% in 2023, then skyrocketed by 97bps to 15.87% in 2024, then surged by 147bps to 7.44% in 2025.
  • Its EBITDA Margin was 7.44% in Q3 2025, compared to 19.36% in Q2 2025 and 38.26% in Q1 2025.